Homology-Based Design for Selective GSK-3 Peptide Inhibitors: Patent Applications and Type 2 Diabetes Mellitus
Camila Chaves Santos, Rodrigo Chaves, Ana Cristina Borges, Michelle Oliveira de Castro and Helio Miranda Costa-Junior
Affiliation: Universidade Gama Filho, Centro de Estudo Multidisciplinar em Diabetes. Rua Manoel Vitorino, 553 – Piedade, Rio de Janeiro - RJ, 20740-900, Brazil.
Keywords: Diabetes mellitus, GSK-3, intracellular signaling, peptide modulator, protein-protein interaction, rational peptide
Protein kinases function in key steps in several physiopathological events; therefore the development of
specific inhibitors to these enzymes presents new opportunities for the treatment of various diseases. Glycogen synthase
kinase 3 (GSK-3) is a constitutively active serine/threonine kinase, whose dysfunction has been linked to several cases of
insulin-resistant type 2 diabetes mellitus, Alzheimer’s disease and mood disorders. These findings make GSK-3 an
attractive target for therapeutics, and several research groups and pharmaceutical companies have made significant efforts
to develop new inhibitors with selective activity to different GSK-3 pathways. One of the strategies applied in the
development of new inhibitors is based on protein-protein interactions between substrates or docking proteins of specific
proteins kinases, creating peptides modulators designed to specifically inhibit those enzymes. Here, we discuss the
development, signaling and the patent applications of specific peptides designed to inhibit GSK-3, their patent status and
their potential uses in the treatment of GSK-3 specific pathologies.
Rights & PermissionsPrintExport